Retatrutide vs Tirzepatide: Triple and Dual Agonism Compared

In July 2026, Eli Lilly announced something that would have sounded like wishful thinking a decade ago: five consecutive positive Phase 3 trials for a single molecule that switches on three metabolic receptors at once. The compound is retatrutide. The trials are called TRIUMPH. And the headline numbers — participants losing an average of 70.3 lbs over 80 weeks — are the largest seen in a pivotal obesity trial to date.

Tirzepatide got there first. It activates two receptors instead of three, it has been on the market since 2022, and it already beat semaglutide in a head-to-head trial. Retatrutide is the follow-up act, and it is not yet approved anywhere.

For researchers, the interesting question is not which one “wins”. It is what happens when you add a third receptor to a molecule that was already working, and why that third receptor changes the metabolic picture so much. Both are discussed here as research subjects only — they are not medicines, not approved for human consumption, and nothing below is supplied or intended for any clinical purpose.

Here is what the science actually shows.

Two Molecules, One Family Tree

Both compounds descend from a simple observation made in the 1960s: gut hormones released after a meal do far more than aid digestion. They signal to the pancreas, the brain, the liver and fat tissue simultaneously. Pharmacology spent the following fifty years learning to imitate that conversation.

The first generation mimicked one hormone — glucagon-like peptide-1, or GLP-1. Semaglutide is the best-known example. The second generation added a second receptor. Tirzepatide activates both GLP-1 and glucose-dependent insulinotropic polypeptide, known as GIP. The third generation, which retatrutide represents, adds glucagon.

That progression matters because each receptor does something different. GLP-1 slows gastric emptying and reduces appetite signalling in the hypothalamus. GIP appears to improve how fat tissue handles nutrients and may reduce the nausea burden that comes with GLP-1 activation. Glucagon — counterintuitively, given its reputation as the hormone that raises blood sugar — increases energy expenditure and drives fat oxidation in the liver.

Stack all three and you are not simply pushing harder on appetite. You are working on intake, nutrient handling and energy output at the same time.

The Hormone Nobody Could Make Useful

The idea behind both molecules is older than most people assume, and for decades it went nowhere.

In 1902, Bayliss and Starling identified a substance released by the gut that stimulated pancreatic secretion. They called it secretin and coined the word “hormone” to describe it. The notion that the intestine talks chemically to the rest of the body was established that early.

The specific observation that made incretin drugs possible came much later. Researchers noticed that glucose taken orally produced a far larger insulin response than the same amount of glucose delivered intravenously. Something released by the gut during digestion was amplifying the pancreatic response. That phenomenon became known as the incretin effect, and by the 1970s the two hormones responsible had been isolated: GIP first, then GLP-1.

Turning that into a drug proved extremely difficult. Native GLP-1 has a half-life of roughly two minutes in circulation. An enzyme called dipeptidyl peptidase-4 clips it apart almost immediately. A hormone that disappears in minutes is not a weekly injection, and for years the pharmacology was interesting but unusable.

The breakthrough came from two directions at once. Sequence modifications at the cleavage site made the peptide resistant to DPP-4. Attaching a fatty acid chain allowed the molecule to bind reversibly to albumin in the bloodstream, creating a circulating reservoir that released slowly. Together those changes stretched a two-minute half-life into something measured in days.

Both tirzepatide and retatrutide are direct descendants of that engineering. The fatty acid moiety on tirzepatide and the fatty diacid on retatrutide are not incidental — they are the reason weekly dosing is possible at all, and they are also the reason both compounds are analytically demanding to manufacture.

The Molecule That Changed the Benchmark

Tirzepatide, developed as LY3298176, is a 39-amino-acid synthetic peptide built on a GIP backbone and engineered to bind both GIP and GLP-1 receptors. A fatty acid moiety attached to the peptide chain extends its half-life enough to support once-weekly subcutaneous dosing.

The SURMOUNT-1 trial established what it could do. Over 72 weeks, participants on the three doses achieved average weight reductions of 16.0% on 5 mg, 21.4% on 10 mg and 22.5% on 15 mg, against 2.4% on placebo. Published in the New England Journal of Medicine, those figures reset expectations for what a metabolic peptide could achieve.

Then came the comparison everyone wanted. SURMOUNT-5 put tirzepatide directly against semaglutide in 751 adults with obesity and no diabetes, over 72 weeks. Tirzepatide produced a mean weight reduction of 20.2%; semaglutide produced 13.7%. The difference was statistically significant, and it was the first head-to-head evidence that dual agonism genuinely outperformed the single-receptor approach rather than simply looking better across separate trials.

Tirzepatide’s research story has since spread well beyond weight. SURMOUNT-OSA examined moderate-to-severe obstructive sleep apnoea in adults with obesity and reported significant reductions in the apnoea-hypopnoea index. Cardiovascular outcome work through SURPASS-CVOT and SURMOUNT-MMO continues, with results anticipated that could expand the evidence base considerably. Post hoc analyses published in the Journal of the American College of Cardiology in June 2026 tracked long-term changes across cardiovascular risk biomarkers.

In regulatory terms, tirzepatide is marketed as Mounjaro for type 2 diabetes, approved in May 2022, and as Zepbound for chronic weight management, approved in November 2023. Same molecule, same doses, different indications. In the UK, NICE approved Mounjaro for type 2 diabetes in adults meeting specified BMI criteria, bringing it into the NHS pathway.

Adding the Third Receptor

Retatrutide, developed as LY3437943, takes the same architectural idea and extends it. It is a single protein conjugated to a fatty diacid moiety, activating human GIP, GLP-1 and glucagon receptors together. Its half-life sits at roughly six days, which supports weekly subcutaneous administration.

The receptor profile is more interesting than “three instead of two” suggests. Cell culture work shows retatrutide is less potent than the body’s own ligands at the glucagon and GLP-1 receptors — roughly 0.3 and 0.4 times as active respectively — while being substantially more potent at the GIP receptor, by a factor of around 8.9.

That is a deliberate balancing act. Glucagon agonism raises energy expenditure, but push it too hard and you risk unwanted effects on glycaemic control. The molecule is tuned to capture the metabolic benefit of glucagon signalling without letting it dominate.

The Counterintuitive Part

Adding glucagon to a weight-loss molecule sounds like a mistake, and it is worth explaining why it isn’t.

Glucagon’s textbook role is raising blood glucose. It is the hormone that opposes insulin, mobilising stored glycogen when blood sugar falls. Deliberately activating that receptor in a compound intended to improve glycaemic control looks, at first glance, like working against yourself.

The resolution lies in what else glucagon does. Beyond glucose mobilisation, glucagon receptor activation increases resting energy expenditure — the body burns more calories at rest. It also drives hepatic lipolysis and fat oxidation, pushing the liver to break down stored triglyceride rather than accumulate it.

In a molecule that simultaneously activates GLP-1 and GIP receptors, the glycaemic downside is offset. GLP-1 agonism enhances glucose-dependent insulin secretion; GIP agonism supports it further. The insulin-promoting effects counterbalance glucagon’s glucose-raising effect, while glucagon’s energy expenditure and fat oxidation effects remain available.

That is the theoretical case for triple agonism, and the receptor potency data suggests the molecule was tuned with exactly this balance in mind. Retatrutide being only 0.3 times as active as native glucagon at the glucagon receptor is not a weakness — it is restraint, calibrated so the metabolic benefit arrives without the glycaemic cost.

The TRANSCEND-T2D-1 results provide the practical test. In adults with type 2 diabetes, retatrutide delivered up to 2% A1C improvement alongside nearly 17% weight loss. If glucagon agonism were undermining glycaemic control, that is precisely where it would show, and it did not.

What the Trials Found

The Phase 2 results, published in the New England Journal of Medicine in 2023, were the first signal that something unusual was happening. Participants with obesity and without type 2 diabetes achieved weight reduction of up to 24.2% at 48 weeks — numbers that exceeded what semaglutide and tirzepatide had produced in their own respective trials at comparable timepoints.

Then the Phase 3 programme began reporting, and it has not stopped.

TRIUMPH-4, announced in December 2025, studied adults with obesity and knee osteoarthritis. The highest dose produced average weight loss of 28.7% — around 71.2 lbs — alongside substantial improvement in osteoarthritis pain and physical function. It was the first successful Phase 3 readout in the programme.

TRANSCEND-T2D-1 reported in March 2026, evaluating retatrutide in adults with type 2 diabetes inadequately controlled by diet and exercise. It met the primary endpoint and all key secondary endpoints, delivering up to 2% A1C improvement and nearly 17% weight loss across 40 weeks. Clinically meaningful improvements appeared across non-HDL cholesterol, triglycerides and systolic blood pressure.

TRIUMPH-1, the pivotal obesity trial, reported in May 2026. Over 80 weeks, participants on 12 mg lost an average of 70.3 lbs — 28.3% of body weight — and 45.3% of participants achieved weight reduction of 30% or greater. All three doses met primary and key secondary endpoints.

TRIUMPH-2 and TRIUMPH-3 followed in July 2026, examining adults with obesity alongside type 2 diabetes and established cardiovascular disease respectively. Both met their primary endpoints.

That makes five positive Phase 3 studies. Lilly has stated it is completing the manufacturing and controls data package required for a Biologics License Application, with submission for US approval planned for the first quarter of 2027. Seven additional Phase 3 readouts were expected across 2026, covering obstructive sleep apnoea, chronic low back pain, cardiovascular and renal outcomes, and maintenance dosing strategies.

The Liver Question

This is the part that often gets overlooked, and it may be where triple agonism separates itself most clearly.

A Phase 2a substudy published in Nature Medicine in June 2024 examined retatrutide in participants with metabolic dysfunction-associated steatotic liver disease. Of 338 participants randomised in the main obesity study, 98 met the inclusion criterion of 10% or greater liver fat content measured by MRI proton density fat fraction. Those participants were randomised across placebo and four retatrutide doses.

The mechanistic argument is straightforward. Glucagon promotes hepatic fat oxidation — the liver’s capacity to burn stored fat. That pathway is simply absent from GLP-1-only agonists and from dual GIP/GLP-1 agonists like tirzepatide. If liver fat reduction is the goal, a molecule with glucagon agonism has a route that the others do not.

A dedicated Phase 3 liver disease trial is examining whether retatrutide can resolve steatohepatitis and fibrosis rather than simply reducing liver fat — a considerably higher bar, and the one that regulatory approval in that indication would require.

Reading the Comparison Honestly

Here is where care is needed, because the temptation to declare a winner is strong and the evidence does not quite support it.

No head-to-head trial between retatrutide and tirzepatide has been conducted. Every comparison between them is a cross-trial comparison, and cross-trial comparisons are genuinely limited. Different trials enrol different populations, run for different durations, use different dose ceilings and apply different statistical estimands. TRIUMPH-1 ran 80 weeks; SURMOUNT-1 ran 72. That difference alone affects the headline percentage.

What can be said fairly is this. Retatrutide’s Phase 3 obesity results — 28.3% at 80 weeks — are numerically larger than tirzepatide’s SURMOUNT-1 results of 22.5% at 72 weeks. The direction is consistent across Phase 2 and Phase 3. And the mechanistic rationale for why triple agonism might outperform dual agonism is coherent rather than merely post hoc.

But tirzepatide has something retatrutide does not: years of real-world use, completed cardiovascular outcome work, approvals across multiple jurisdictions, and a head-to-head victory over its closest competitor. Retatrutide has five positive Phase 3 trials and a regulatory submission still ahead of it.

The tolerability picture is also worth stating plainly. In TRANSCEND-T2D-1, the most common adverse events with retatrutide at 4 mg, 9 mg and 12 mg were nausea at 16.4%, 19.5% and 26.5% respectively against 3.7% with placebo, and diarrhoea at 18.7%, 26.3% and 22.8%. These are consistent with the event types seen across incretin-based therapies — tirzepatide’s SURMOUNT-1 reported nausea at 24.6% to 33.3% across doses — but they are real, dose-related and not trivial.

Why Purity Matters More Than Usual Here

Both compounds present a genuine analytical challenge, and it comes down to structure.

Tirzepatide is 39 amino acids long. Retatrutide is a comparably complex single protein. Both carry fatty acid or fatty diacid conjugations that are essential to their half-life and receptor behaviour. Solid-phase peptide synthesis builds these chains one residue at a time, and every coupling step is an opportunity for a truncated sequence, a deletion, or an incompletely conjugated product to form.

The longer and more modified the peptide, the more of those opportunities exist. A 39-residue chain with a lipid modification is not remotely comparable to a five-residue peptide in manufacturing terms, and purity figures should be read with that in mind.

The specific failure modes are worth understanding, because they determine what a chromatogram is actually showing you.

Deletion sequences occur when a coupling step fails and the synthesis continues without that residue. The result is a peptide one amino acid short — close enough in mass and behaviour to be difficult to separate, different enough to alter receptor binding. On a 39-residue chain, there are 38 opportunities for this to happen.

Truncated sequences arise when synthesis terminates early. These are generally easier to separate chromatographically because the mass difference is larger, but they still consume yield.

Incomplete conjugation is specific to lipid-modified peptides like these two. If the fatty acid or fatty diacid fails to attach, the resulting molecule has the correct amino acid sequence but lacks the modification responsible for its extended half-life. Mass spectrometry catches this because the molecular weight is wrong. Sequence analysis alone would not.

Racemisation — where an amino acid flips from the L to the D configuration during coupling — produces a molecule with identical mass and a different three-dimensional shape. Mass spectrometry cannot distinguish it. This is one reason chromatographic separation matters alongside mass confirmation rather than instead of it.

Each of these produces a different signature on the analysis, and each has different implications for research use. A batch at 99% purity with the remaining 1% consisting of a single deletion sequence is a very different proposition from one where the same 1% is a mixture of unconjugated product and racemised material.

This is why every batch Crown Peptides supplies carries its own certificate of analysis rather than a figure carried across from a previous production run. Purity is measured by high-performance liquid chromatography, which separates the target compound from related substances and reports the main peak as a proportion of total peak area. Identity is confirmed independently by mass spectrometry, which measures molecular weight directly and verifies that the compound present is the sequence intended rather than something structurally adjacent.

Both matter, and neither substitutes for the other. A sample can be highly pure and still be the wrong molecule. It can be correctly identified and still carry a significant fraction of truncated sequences. Running both tests, on every batch, and publishing the result against that batch number is the only way to know what is actually in the vial.

Storage compounds the point. Lipid-modified peptides of this size are supplied lyophilised and should be kept at −20°C for long-term stability, protected from light and from repeated freeze-thaw cycles. Once reconstituted, stability windows shorten considerably. Handling that gets casual after reconstitution can undermine material that arrived at 99% purity.

You can browse the published certificate for any batch through the Crown Peptides lab reports library, or scan the QR code on any vial to open that batch’s report directly.

The UK Picture

The regulatory positions of these two compounds in the UK could hardly be more different, and the distinction is worth stating precisely because it is frequently blurred.

Tirzepatide holds marketing authorisation as a medicine. It is prescribed as Mounjaro for type 2 diabetes, and NICE has approved it for adults meeting defined BMI criteria, placing it within the NHS treatment pathway. That process involved the MHRA assessing safety, efficacy and manufacturing quality, followed by NICE assessing cost-effectiveness. It is a licensed medicine with a defined indication, a summary of product characteristics and a prescriber.

Retatrutide holds no such authorisation anywhere. Lilly’s stated plan is a US Biologics License Application in the first quarter of 2027, with global submissions to follow. Until a regulator completes that assessment, it remains an investigational compound.

These are different categories, and the difference is not a technicality. A licensed medicine has been through a specific evaluation for a specific population and indication. An investigational compound, however promising its trial data, has not.

Research-grade material sits outside both categories entirely. It is supplied for laboratory work — receptor binding studies, analytical method development, stability work, comparative pharmacology — and the certificate of analysis that accompanies it describes what the material is, not what it may be used for.

Where the Research Goes Next

The obvious trajectory is more receptors. If two outperformed one and three outperformed two, four becomes an inevitable question, and several groups are exploring combinations that add amylin or PYY signalling to the incretin backbone.

But the more interesting near-term question is about maintenance rather than magnitude. Lilly’s TRIUMPH programme includes a 4 mg maintenance dose alongside the 9 mg and 12 mg doses used to drive initial weight reduction — an acknowledgement that the dose required to achieve a metabolic change and the dose required to hold it may be different. That distinction has been underexplored across the whole incretin class, and it is where a great deal of practical research interest now sits.

The indication spread is widening too. Retatrutide’s Phase 3 programme spans obesity, type 2 diabetes, knee osteoarthritis, obstructive sleep apnoea, chronic low back pain, cardiovascular and renal outcomes, and steatotic liver disease. Tirzepatide’s programme has followed a similar arc. What began as glucose control has become a platform for investigating conditions connected by metabolic dysfunction rather than by organ system — which is a genuinely different way of thinking about what these molecules are for.

For laboratory work, that breadth is the opportunity. The receptor pharmacology is well characterised, the trial literature is rich and current, and the mechanistic questions about how glucagon agonism interacts with GIP and GLP-1 signalling remain open enough to be worth investigating.

Common Questions

What is the actual difference between retatrutide and tirzepatide?

Tirzepatide activates two receptors — GIP and GLP-1. Retatrutide activates three, adding glucagon. That third receptor brings a mechanism the others lack: increased energy expenditure and hepatic fat oxidation, rather than acting only on appetite and nutrient handling.

Is retatrutide more effective than tirzepatide?

Cross-trial numbers point that way, with retatrutide’s TRIUMPH-1 reporting 28.3% weight reduction at 80 weeks against tirzepatide’s 22.5% at 72 weeks in SURMOUNT-1. But no head-to-head trial has compared them, and trials with different durations, populations and dose ceilings cannot be read as a direct contest.

Where is retatrutide in the regulatory process?

Lilly has reported five positive Phase 3 trials and stated it plans to submit a Biologics License Application for US approval in the first quarter of 2027, once the manufacturing and controls data package is complete. It remains investigational.

Why does retatrutide show liver benefits that tirzepatide does not?

Glucagon receptor agonism promotes hepatic fat oxidation. That pathway is not present in GLP-1-only or dual GIP/GLP-1 agonists. A Phase 2a substudy published in Nature Medicine examined this in participants with 10% or greater liver fat content, and a dedicated Phase 3 liver trial is examining whether the effect extends to resolving steatohepatitis and fibrosis.

What purity should these compounds be supplied at?

For analytical work, ≥98% is the standard worth holding to, confirmed by HPLC for purity and mass spectrometry for identity, with a certificate tied to the specific batch number. Given the chain length and lipid modification involved in both compounds, a figure without a batch-specific certificate behind it is not a measurement.

How should they be stored?

Lyophilised material at −20°C for long-term storage, protected from light. Avoid repeated freeze-thaw cycles. Once reconstituted, stability windows shorten substantially and material should be handled accordingly.

The Short Version

Tirzepatide proved that adding a second receptor to the incretin approach produced a measurable step change, and it holds the only head-to-head victory in the class. Retatrutide is testing whether a third receptor produces another, and across five Phase 3 trials the evidence so far says it might.

Neither story is finished. Retatrutide’s regulatory submission is still ahead of it, seven further Phase 3 readouts are working through, and the maintenance-dose question is barely begun. For anyone running metabolic research, that combination — well-characterised pharmacology, active trial pipeline, open mechanistic questions — is about as good as it gets.

Every compound Crown Peptides supplies is HPLC and mass spectrometry verified, with the full certificate of analysis published against its batch number. Explore the metabolic research peptide range to see what is currently available.